American Diabetes Association Scientific Sessions
EMPRISE: Empagliflozin demonstrates CV safety, efficacy in real-world population
Two interim analyses of the EMPRISE study supported the effectiveness and CV safety of the SGLT2 inhibitor empagliflozin in real-world patients compared with DPP-IV inhibitors and GLP-1 receptor agonists.
Bempedoic acid lowers LDL regardless of glycemic status
Researchers found that bempedoic acid significantly reduced LDL compared with placebo in patients with diabetes, prediabetes or normoglycemia and hypercholesterolemia.
Immune checkpoint inhibitors may induce hyperglycemia, worsen insulin resistance for some
A subset of patients with cancer who received an immune checkpoint inhibitor developed new hyperglycemia, suggesting the therapy may play a role in immune-related insulin resistance.
SEARCH: HbA1c rising for youths with diabetes despite technology, new therapies
A substantial percentage of youths and young adults with diabetes in the U.S. are not achieving recommended glycemic outcomes despite newer therapies and greater availability of diabetes technology, according to SEARCH study data.
VERTIS-CV: Ertugliflozin CV neutral, HF benefit seen in type 2 diabetes
Adults with type 2 diabetes and established atherosclerotic cardiovascular disease were no more likely to experience a CV event during 3.5 years of follow-up with the SGLT2 inhibitor ertugliflozin compared with placebo, study data show.
TEDDY data: Early type 1 diabetes signals, environmental triggers and diet associations
Analyses from the ongoing TEDDY study suggest that islet autoimmunity develops by age 2 years for many children who go on to develop type 1 diabetes, and certain illnesses, gut microbiota and even diet may affect disease progression.
DAPA-HF: Dapagliflozin reduces new-onset diabetes among adults with heart failure
Adults with heart failure assigned the SGLT2 inhibitor dapagliflozin had a 32% lower risk for new-onset type 2 diabetes over 18 months of follow-up vs. placebo, according to a planned analysis of DAPA-HF trial data.
The ‘cardiometabolic dilemma’: Collaboration across specialties advances diabetes research
More must be done across cardiology, endocrinology, obesity medicine and related specialties to build on a century of progress and one day prevent or even cure all types of diabetes, according to a speaker.
Novel insulin sensor under development for point-of-care testing, insulin-delivery devices
A wearable microneedle, multifluidic insulin-sensing device may one day allow closed-loop insulin-delivery systems to directly test insulin levels, which in turn might help increase time in range for people with type 1 diabetes.
Medicaid expansion yields ‘positive effects’ on diabetic foot ulcer care for US minorities
Hospital admissions for diabetic foot ulcers among nonwhite U.S. residents with Medicaid coverage nearly doubled in states that were early adopters of Affordable Care Act expansion programs, according to study data.